Prognostic Value of Postinduction Chemotherapy Volumetric PET/CT Parameters for Stage IIIA or IIIB Non–Small Cell Lung Cancer Patients Receiving Definitive Chemoradiotherapy

The aim of this follow-up analysis of the ESPATUE phase 3 trial was to explore the prognostic value of postinduction chemotherapy PET metrics in patients with stage III non–small cell lung cancer who were assigned to receive definitive chemoradiotherapy. Methods: All eligible stage IIIA (cN2) and stage IIIB patients in the trial received an induction doublet chemotherapy consisting of 3 cycles with cisplatin and paclitaxel, and subsequent...